证券日报网讯 11月27日晚间，新华制药发布公告称，近日，公司收到国家药品监督管理局核准签发的 盐酸肾上腺素注射液（简称"本品"）《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性 评价。 （文章来源：证券日报） ...

本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长 浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 格隆汇11月27日丨新华制药(000756.SZ)公布，公司收到国家药品监督管理局核准签发的盐酸肾上腺素 注射液（以下简称"本品"）《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。 ...

智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸肾上腺素注 射液《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管 痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时 间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 ...

新华制药11月27日公告，公司近日收到国家药品监督管理局核准签发的盐酸肾上腺素注射液《药品补充 申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管痉挛所致严重 呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时间，是各种原因 引起的心脏骤停进行心肺复苏的主要抢救用药。 ...

Core Viewpoint - The announcement indicates that the company has received approval from the National Medical Products Administration for its epinephrine injection, which has passed the consistency evaluation of quality and efficacy for generic drugs [1] Group 1: Company Developments - The company submitted the application materials in February 2024 and received acceptance, with approval granted in November 2025 [1] - The epinephrine injection is indicated for severe respiratory distress and anaphylactic shock, classified as a Category A drug under medical insurance [1] Group 2: Market Insights - The estimated sales of epinephrine in Chinese public medical institutions is approximately 270 million yuan in 2024 [1] - The successful evaluation is expected to enhance the company's market competitiveness, although drug sales are subject to uncertainties influenced by policies and market conditions [1]

智通财经APP讯，新华制药(000756.SZ)公告，公司收到国家药品监督管理局核准签发的盐酸肾上腺素注 射液《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致性评价。本品主要适用于因支气管 痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长浸润麻醉用药的作用时 间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 ...

本品主要适用于因支气管痉挛所致严重呼吸困难，可迅速缓解药物等引起的过敏性休克，亦可用于延长 浸润麻醉用药的作用时间，是各种原因引起的心脏骤停进行心肺复苏的主要抢救用药。 格隆汇11月27日丨山东新华制药股份(00719.HK)公布，近日，公司收到国家药品监督管理局核准签发的 盐酸肾上腺素注射液(以下简称"本品")《药品补充申请批准通知书》，本品通过仿制药质量和疗效一致 性评价。 ...

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) announced that its subsidiaries, Tianjin Peace Pharmaceutical Co., Ltd. and Hubei Tian Pharmaceutical Co., Ltd., participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1 - The subsidiaries involved in the procurement are Tianjin Peace Pharmaceutical and Hubei Tian Pharmaceutical [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1]

Core Viewpoint - The company announced that its subsidiaries participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with seven products expected to be selected for this procurement [1] Group 1: Procurement Participation - The subsidiaries of the company, Tianjin Pharmaceutical Peace Pharmaceutical Co., Ltd. and Hubei Tianjin Pharmaceutical Co., Ltd., are involved in the national centralized drug procurement [1] - The seven products proposed for selection include Betamethasone Sodium Phosphate Injection, Ambroxol Hydrochloride Injection, Metoclopramide Hydrochloride Injection, Theophylline Injection, Isoniazid Injection, Adrenaline Hydrochloride Injection, and Famotidine Injection [1] Group 2: Financial Impact - The total projected sales revenue from the selected products for the year 2024 is approximately 95.16 million yuan, accounting for 2.96% of the company's total revenue for that year [1] - For the first three quarters of 2025, the projected sales revenue from these products is approximately 22.08 million yuan, representing 0.99% of the company's revenue for that period [1]